Kastia (Rosuvastatin)

Rosuvastatin blocks the enzyme HMG‑CoA reductase, the rate‑limiting step in cholesterol synthesis. Inhibiting this enzyme reduces hepatic production of cholesterol, prompting the liver to increase LDL‑receptor expression and clear more LDL particles from the bloodstream, which results in lower plasma cholesterol levels.

The appropriate dose of Kastia is individualized by the prescribing healthcare professional based on the patient’s cholesterol levels, cardiovascular risk profile, age, renal function, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Rosuvastatin is classified as Pregnancy Category X, meaning it is contraindicated during pregnancy because it can cause fetal harm. It is also not recommended for breastfeeding mothers, as the drug may be excreted in breast milk and affect the infant.

To request Kastia, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kastia (rosuvastatin) is a high‑potency statin that often achieves greater LDL‑cholesterol reductions at lower doses compared with older agents such as simvastatin or pravastatin. Its pharmacokinetic profile provides a longer half‑life, allowing flexible dosing, but clinicians still consider individual patient factors and potential drug interactions when selecting a statin.

Kastia should be stored at room temperature, below 25 °C, in the original packaging to protect it from moisture and light. Keep the product out of reach of children and do not use it after the expiry date printed on the label.

Kastia is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not crushed or chewed unless specifically instructed by a healthcare professional.

The most serious adverse events linked to rosuvastatin include rhabdomyolysis (severe muscle breakdown), significant elevations in liver enzymes indicating hepatic injury, and rare severe allergic reactions such as anaphylaxis. Patients should report unexplained muscle pain, dark urine, jaundice, or signs of an allergic response promptly.

Kastia should not be used by individuals with known hypersensitivity to rosuvastatin or any component of the formulation, pregnant women, or nursing mothers. Caution is also advised for patients with severe hepatic impairment, active liver disease, or those taking contraindicated medications such as gemfibrozil.